| scholarly article | Q13442814 |
| P2093 | author name string | Liang Zhang | |
| Ping Bie | |||
| Feng Xia | |||
| Wan-Yee Lau | |||
| Li-Li Wu | |||
| Da-Peng Yang | |||
| Hong-Bo Huan | |||
| Xi-Shu Wang | |||
| Xu-Dong Wen | |||
| P2860 | cites work | A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. | Q54232269 |
| Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? | Q56781617 | ||
| Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation | Q59901689 | ||
| Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study | Q74014765 | ||
| A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma | Q80376325 | ||
| Intraoperative radiofrequency thermal ablation combined with portal vein infusion chemotherapy and transarterial chemoembolization for unresectable HCC | Q81301825 | ||
| Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone | Q83480555 | ||
| Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis | Q84130046 | ||
| Risk of recurrence in hepatitis B-related hepatocellular carcinoma: impact of viral load in late recurrence | Q84549847 | ||
| Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization | Q84620199 | ||
| Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis | Q26860637 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide | Q29616215 | ||
| Hepatocellular carcinoma | Q29616359 | ||
| Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival | Q29616865 | ||
| Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial | Q29617955 | ||
| Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data | Q30627447 | ||
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials | Q31014850 | ||
| Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial | Q33370654 | ||
| Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection | Q33398383 | ||
| Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data | Q33412969 | ||
| Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach | Q33556245 | ||
| Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists | Q33600372 | ||
| Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma | Q34225588 | ||
| Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma | Q34225751 | ||
| Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis | Q34265805 | ||
| Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma | Q34593071 | ||
| Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma | Q34611545 | ||
| Comparative effectiveness of radiofrequency ablation with or without transarterial chemoembolization for hepatocellular carcinoma | Q35033273 | ||
| Loco-regional treatment of hepatocellular carcinoma | Q37766546 | ||
| Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis | Q38071906 | ||
| Treatment outcomes of transcatheter arterial chemoembolization combined with local ablative therapy versus monotherapy in hepatocellular carcinoma: a meta-analysis | Q38146836 | ||
| Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis | Q39207781 | ||
| TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials | Q39295492 | ||
| Individual- and trial-level surrogacy in colorectal cancer | Q40122418 | ||
| Transarterial chemoembolization in combination with local therapies for hepatocellular carcinoma: a meta-analysis | Q41761634 | ||
| Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma | Q43032055 | ||
| Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. | Q43647764 | ||
| Long-term interferon maintenance therapy improves survival in patients with HCV-related hepatocellular carcinoma after curative radiofrequency ablation. A matched case-control study | Q43648648 | ||
| Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels | Q44027427 | ||
| Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus | Q44314372 | ||
| Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. | Q44401177 | ||
| Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized-controlled trials | Q45832995 | ||
| Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma | Q46838376 | ||
| The validation of surrogate endpoints in meta-analyses of randomized experiments | Q47671365 | ||
| P433 | issue | 52 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 90291-90300 | |
| P577 | publication date | 2017-06-29 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients' data | |
| P478 | volume | 8 |
| Q53699885 | LncRNA NR2F1-AS1 regulates hepatocellular carcinoma oxaliplatin resistance by targeting ABCC1 via miR-363. | cites work | P2860 |
Search more.